A functional genetic screen defines the AKT-induced senescence signaling network by Chan, Keefe T. et al.
Cell Death & Differentiation (2020) 27:725–741
https://doi.org/10.1038/s41418-019-0384-8
ARTICLE
A functional genetic screen deﬁnes the AKT-induced senescence
signaling network
Keefe T. Chan 1,2 ● Shaun Blake1 ● Haoran Zhu1,2 ● Jian Kang1 ● Anna S. Trigos1,2 ● Piyush B. Madhamshettiwar3 ●
Jeannine Diesch4 ● Lassi Paavolainen5 ● Peter Horvath6 ● Ross D. Hannan 1,2,7,8,9,10 ● Amee J. George7,8,11 ●
Elaine Sanij1,11 ● Katherine M. Hannan7,9 ● Kaylene J. Simpson2,3 ● Richard B. Pearson 1,2,9,10
Received: 12 February 2019 / Revised: 30 May 2019 / Accepted: 19 June 2019 / Published online: 8 July 2019
© The Author(s) 2019. This article is published with open access
Abstract
Exquisite regulation of PI3K/AKT/mTORC1 signaling is essential for homeostatic control of cell growth, proliferation, and
survival. Aberrant activation of this signaling network is an early driver of many sporadic human cancers. Paradoxically,
sustained hyperactivation of the PI3K/AKT/mTORC1 pathway in nontransformed cells results in cellular senescence, which
is a tumor-suppressive mechanism that must be overcome to promote malignant transformation. While oncogene-induced
senescence (OIS) driven by excessive RAS/ERK signaling has been well studied, little is known about the mechanisms
underpinning the AKT-induced senescence (AIS) response. Here, we utilize a combination of transcriptome and metabolic
proﬁling to identify key signatures required to maintain AIS. We also employ a whole protein-coding genome RNAi screen
for AIS escape, validating a subset of novel mediators and demonstrating their preferential speciﬁcity for AIS as compared
with OIS. As proof of concept of the potential to exploit the AIS network, we show that neuroﬁbromin 1 (NF1) is
upregulated during AIS and its ability to suppress RAS/ERK signaling facilitates AIS maintenance. Furthermore, depletion
of NF1 enhances transformation of p53-mutant epithelial cells expressing activated AKT, while its overexpression blocks
transformation by inducing a senescent-like phenotype. Together, our ﬁndings reveal novel mechanistic insights into the
control of AIS and identify putative senescence regulators that can potentially be targeted, with implications for new
therapeutic options to treat PI3K/AKT/mTORC1-driven cancers.
Introduction
The PI3K/AKT/mTORC1 pathway integrates signals from
growth factor stimulation, nutrient and energy status,
hypoxia and cellular stress to control cell growth, pro-
liferation and survival, cellular metabolism, migration, and
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angiogenesis [1]. Recurrent PI3K/AKT/mTORC1 altera-
tions, particularly activating hotspot PIK3CA mutations
(E545K and H1047R) or inactivating PTEN mutations,
occur in 30% of human sporadic tumors [2, 3]. Some
(1.4–8%) breast, colorectal, and ovarian cancers display an
AKT-E17K mutation conferring constitutive activation [4].
Furthermore, pathway hyperactivation occurs in breast
(20–55%), lung (~60%), prostate (50%), and melanomas
(40–70%) [5], driving preneoplastic lesions in lung, breast,
and endometrial cancers [6–8]. Nevertheless, malignant
disease progression requires additional genomic hits.
Understanding deregulated signaling in normal cells will
unveil key regulatory mechanisms that, if subverted, would
allow malignant progression and identify therapeutic
opportunities if these tumor-suppressive “brakes” were
restored.
Excessive RAS/ERK pathway activation driving
oncogene-induced senescence (OIS) is one such brake [9–
12]. OIS is well characterized, featuring p16 upregulation, a
persistent DNA damage response (DDR), senescence-
associated heterochromatic foci (SAHF), enhanced SA-
beta-galactosidase (SA-ßGal) activity, a SA-secretory phe-
notype (SASP), and cell cycle arrest [9, 13, 14]. However,
additional genetic and epigenetic perturbations can reverse
OIS to promote cancer development [15, 16]. Lymphocytes
in Eµ-Nras mice display strong SA-ßGal activity; however,
loss of the histone methyltransferase Suv39h1 impairs SA-
ßGal activity and causes T-cell lymphoma [10]. Con-
stitutively active BrafV600E promotes senescence in mela-
nocytic nevi, but Pten depletion drives melanomagenesis
[17]. Investigating OIS has also uncovered targeted therapy
resistance mechanisms. Neuroﬁbromin 1 (NF1) deﬁciency
overcame BrafV600E-induced senescence and conferred
BRAF inhibitor resistance in melanoma [18, 19].
We and others have demonstrated chronic PI3K/AKT/
mTORC1 pathway activation promotes an OIS-like phe-
notype, termed AKT-induced senescence (AIS) [20–22],
with PIK3CA mutants, PTEN knockdown, and con-
stitutively active AKT triggering AIS [20]. Unlike OIS, AIS
lacked a hyperproliferative burst and DNA damage, and
proliferative arrest relied on p53 rather than p16. Increased
p53 expression depended on mTORC1-dependent mRNA
translation and MDM2’s nucleolar sequestration. Similarly,
activated Akt or Pten knockout in murine prostate epithe-
lium promoted intraepithelial neoplasia and senescence
marker expression [21, 23], while subsequent Cdkn1b or
Trp53 loss facilitated adenocarcinoma progression and
senescence marker loss. We hypothesize that, like OIS, AIS
is a reversible tumor-suppressive mechanism, and under-
standing how it is overcome will identify mechanisms of
tumorigenesis and therapeutic resistance in the 38% of
human solid cancers with deregulated PI3K/AKT/mTORC1
activity [3].
Here, we provide insight into AIS using transcriptomic
and metabolomic proﬁling, demonstrating overlapping sig-
natures with OIS. We reveal suppression of RAS/ERK
signaling is a unique AIS hallmark. Moreover, we screened
the protein-coding genome and identiﬁed numerous escape
routes beyond p53 loss. Employing genetic approaches, we
validated high-conﬁdence candidates in common with OIS
and speciﬁc for AIS, demonstrating NF1-mediated sup-
pression of RAS-ERK signaling maintains AIS. We further
show NF1 loss promotes AKT-dependent transformation of
fallopian tube epithelial cells and its functional restoration
reinstates a p53-independent senescence-like phenotype.
Methods and materials
Cell lines
BJ-TERT-immortalized human foreskin ﬁbroblasts were a
gift from Robert Weinberg (Massachusetts Institute of
Technology) [24]. Primary IMR-90 lung ﬁbroblasts origi-
nating from the American Type Culture Center (ATCC
CCL-186) were obtained from the Garvan Institute of
Medical Research. The human fallopian tube epithelial cell
line FT282, which is telomerase reverse transcriptase
(TERT)-immortalized and overexpresses mutant p53-
R175H [25], was generated by Ronny Drapkin and col-
leagues (University of Pennsylvania) and provided to us.
Human embryonic kidney (HEK293T) cells were purchased
from the ATCC (ATCC-CRL-3216). All cells were tested
for mycoplasma contamination prior to experimentation and
intermittently tested thereafter by PCR. BJ-TERT cells were
cultured in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM)
(Gibco™ #11965084)+20 mM HEPES, 17% Medium 199
(Gibco™ #11150067), 15% fetal bovine serum (FBS), and
1% GlutaMAX™ l-alanyl-l-glutamine dipeptide (Gibco™
#35050061). IMR-90 cells were cultured in Eagle’s mini-
mum essential medium supplemented with 10% FBS, 5 mM
sodium pyruvate (Gibco™, #11360070), 1% nonessential
amino acids (Gibco™, #11140050), and 1% GlutaMAX™.
HEK-293T cells were cultured in DMEM +20 mM HEPES,
10% FBS, and 1% GlutaMAX™. FT282 cells were cultured
in DMEM:F12 (1:1) and 2% Ultroser™ G serum substitute
(Bio-Strategy #PALS15950-017). All cell lines were
maintained at 37 °C with 5% CO2 except for IMR-90 (3%
O2) in a humidiﬁed incubator. Cell numbers were deter-
mined using a Z2 Coulter counter (Beckman Coulter).
Plasmids, virus production, and transduction
pBABE-puro, pBabe-puro-HA-myrAKT1, and pBabe-
puro-HRASG12V were described previously [20]. The
PHAGE-PmiR-146a-GFP-PGK-puro plasmid [26] was a
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kind gift from Stephen Elledge and the puromycin cassette
was modiﬁed by replacing with the ﬂuorescent selectable
marker mCherry. pCW57.1-4EBP1_4xAla was deposited
by David Sabatani (Addgene 38240) and HA-myrAKT1
and HRASG12V were directly subcloned into this vector to
generate pCW57.1-myrAKT1 and pCW57.1-HRASG12V.
The doxycycline-inducible mirE small hairpin RNA
(shRNA) expression vector REBIR was modiﬁed by Sang-
Kyu Kim (Peter MacCallum Cancer Center) from the ori-
ginal TRMPVIR plasmid [27] by substituting Venus with
enhanced blue ﬂuorescent protein (EBFP2). 97-mer shRNA
sequences are listed in Supplementary Table S11. Out of the
three to four hairpins tested for functional knockdown in
BJ-TERT cells, the two best shRNA hairpins were sub-
cloned into the REBIR construct. Control (REN) and NF1
#2 shRNA hairpins were subcloned into the pGIPZ lenti-
viral shRNA plasmid (Dharmacon™). HEK293T cells were
used for virus production and viral transductions were
performed as previously described [20]. BJ-TERT cells
retrovirally transduced with REBIR shRNA were isolated
by FACS, sorting for EBFP2+/dsRED2+ cells after 72 h
incubation with 2 μg/mL doxycycline (Sigma-Aldrich®
#D9891). Each cell line underwent three consecutive rounds
of sorting. The REBIR plasmid was modiﬁed to generate an
inducible overexpression construct RT3-puro by excising
the dsRed2/mirE cassette and replacing EBFP2 with the
puromycin resistance gene. FLAG-tagged NF1 GTPase
activating protein-related domain (GRD) corresponding to
amino acids 1194-5131 ampliﬁed from R777-E139 Hs.
NF1, which was a gift from Dominic Esposito (Addgene
70423), was subcloned into RT3-puro downstream of the
TRE3G promoter. Cells were selected for using 1 µg/mL
puromycin. FT282 cells expressing RT3-puro-NF1-GRD
were single cell cloned and expanded due to puromycin
cross-resistance. MSCV-Cherry construct harboring HA-
myrAKT1 has been previously described [20].
Gas chromatography mass spectrometry
Cells were plated in six-well plates at 2 × 104 cells/well
density four days before harvest. Prior to harvesting, cells
were washed with 3 mL 37 °C saline and treated with 3 mL
liquid nitrogen until boiled off. Metabolite samples were
harvested using ice-cold methanol:chloroform:scyllo-inosi-
tol (MeOH:CHCl3 9:1 [v/v], 3 µM scyllo-inositol as internal
standard) solution. Samples were transferred to 1.5-mL
tubes and centrifuged to create an upper aqueous (MeOH)
and lower organic layers (CHCl3). Supernatant was trans-
ferred to new tubes and snap frozen. For gas chromato-
graphy mass spectrometry (GC-MS) analysis, 300 µL of the
aqueous phase was evaporated to dryness under vacuum at
4 °C. Samples were derivatized with 25 µL methoxyamine
(30 mg/ml in pyridine, Sigma® #226904) for 60 min at 50 °C
with mixing at 900 rpm, followed by trimethylsilylation
with 25 µL BSTFA+ 1% TMCS (Thermo Scientiﬁc™ #TS-
88530) for 60 min at 50 °C with mixing at 900 rpm. The
derivatized sample (1 µL) was injected onto a Shimadzu
GC/MS-TQ8040 system. Metabolites were normalized
based on pooled metabolite peak area median and identiﬁed
based on GC retention time and mass spectra as compared
with authentic standards and in conjunction with MSD
ChemStation Data Analysis Application (Agilent) using in-
house and Wiley metabolite libraries. Statistical analyses
were performed using Student’s t test. Metabolites were
considered to be signiﬁcant if their adjusted p-values after
Benjamini and Hochberg (BH) correction were less than
0.05. Further data analysis and enrichment analysis were
performed through MetaboAnalyst 4.0.
Functional genomics RNAi screen
Full detailed methods for the functional genomics AIS
escape screen are published in [28]. BJ-TERT cells were
retrovirally transduced with myristoylated AKT1 (myr-
AKT1), establishing a senescent cell population, as we
utilized for RNA-sequencing (RNA-seq) analysis. At 6 days
post transduction (dpt), AIS cells were reverse transfected in
384-well plates using the siGENOME® SMARTpool library
to knock down 18,120 genes in an annotated, well-by-well
format. RNA-seq of BJ-TERT ﬁbroblasts (see below RNA
sequencing and analysis) was used to ﬁlter 3,828 genes not
expressed based on a raw count of 0 from three biological
replicates, and were thus excluded to eliminate false posi-
tives. Seed analysis of the siRNAs corresponding to the 838
hits demonstrated minimal off-target siRNA effects. Gene
ontology analysis of the primary screen hits was performed
using MetaCore™ from GeneGo (Thomson Reuters) with
functional processes associated with the top upregulated
genes having a robust Z-score > 2. Gene network analysis of
the hits duplex screen was performed with NetworkAnalyst
(www.networkanalyst.ca/). Network was generated using
the protein–protein interaction database from the STRING
interactome with a conﬁdence score cutoff of 900 and
illustrated using Inkscape 0.92.2 software.
siRNA transfection of IMR-90 ﬁbroblasts
IMR-90 cells transduced with pBabe-puro empty vector
control or pBabe-puro-myrAKT1 were trypsinized and
counted at 6 dpt and reverse transfected in 12-well plates
(for western immunoblotting) or 96-well black polystyrene
clear ﬂat bottomed plates (Corning® #3603) for staining at
a density of 1.5 × 104 cells/cm2 with 0.375 μL Dharmafect
1/cm2 and 20 nM SMARTpool siRNA (Dharmacon™).
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SA-ßGal staining and EdU labeling
Ten µM EdU (5-ethyl-2′deoxyuridine) was spiked into
culture media for 24 h prior to cell ﬁxation with 2% par-
aformaldehyde/0.2% glutaraldehyde. Histochemical SA-
ßGal staining was performed as described previously [29]
for 24 h. Cells were permeabilized with 0.5% TritonX-100
in PBS, and EdU was ﬂuorescently labeled using the Click-
iT™ EdU Alexa Fluor™ 488 imaging kit (Invitrogen™
#C10337) as per the manufacturer’s instructions. Finally,
nuclei were counterstained with 500 ng/mL 4′,6-diamidino-
2-phenylindole (DAPI) in PBS. Ten random ﬁelds were
imaged with an Olympus BX61 or Zeiss Axio Vert.A1 light
microscope using a 20× objective. More than 100 nuclei
were manually counted and the percent SA-ßGal and EdU-
positive cells were quantiﬁed.
Western immunoblotting
Whole cell lysates were prepared in western solubilization
buffer as previously described [20]. Protein was transferred
to PVDF membranes, which were blocked in 5% skim-milk
TBS 0.1% Tween® 20 (TBST) for 45 min at RT. Mem-
branes were incubated with primary antibodies overnight (4
°C), washed three times in TBST for 10 min, incubated with
HRP-conjugated secondary antibodies for 1 h at room
temperature, and then washed. Membranes were visualized
using Western Lightning™ Plus enhanced chemilumines-
cence (Perkin Elmer) by exposure to ﬁlm (Fujiﬁlm
SuperRX) or imaged by a ChemiDoc™ Touch Imaging
System (Bio-Rad Technology). Digital scans of ﬁlm were
acquired using an Epson Perfection V700 Photo at ≥300
dpi. A list of antibodies used is available in Supplementary
Table S12. Ras activity was assessed using the Active Ras
Detection Kit (Cell Signaling Technology® #8821) accord-
ing to the manufacturer’s instructions.
Gene expression analysis
Total RNA was extracted using the ISOLATE-II (Bioline)
or RNeasy® Mini Kit (Qiagen) as per the manufacturer’s
instructions. One μg of total RNA was used as a template
for cDNA synthesis using SuperScript™ III reverse tran-
scriptase (Invitrogen™ #18080093), hexameric random
primers, and dNTPs. Quantitative real-time PCR (qRT-
PCR) reactions were performed using Fast SYBR® Green
reagents in a StepOnePlus™ Real-Time PCR system
(Applied Biosystems™) with a +0.7 °C melt increment.
Changes in target gene expression were normalized to
GAPDH housekeeping genes and fold change was deter-
mined by using 2^(−ΔΔCt). Primer sequences are listed in
Supplementary Table S13.
RNA-sequencing and analysis
Poly-A selective RNA-seq libraries were prepared using the
TruSeq RNA sample preparation kit (Illumina®) and
sequenced on an Illumina® Genome Analyzer IIx (pool of
six samples per lane) or Illumina® NextSeq 500. The quality
of the generated 50 bp paired-end reads from BJ-TERT cells
(AIS versus proliferating) was assessed with FastQC 0.11.2.
Tophat2 (version 2.0.13)/Bowtie2 (version 2.2.3.0) or
HISAT2 (version 2.0.4) for the 75 bp single reads (OIS
versus pBabe) [30], which were used for alignment to the
genome (hg19/GRCh37). Cutadapt (version 1.7.1 with
Python 2.7.8) was used for adapter and quality trimming.
Picard 1.125 was used to generate BAM indices and to
calculate insert size. Samtools 0.1.18 was used to sort and
merge. Reads were counted using featurecounts (version
1.6.2) in Galaxy [31]. The differential expression of genes
was then calculated utilizing the DESeq2 package v1.24.0
and plotted in R [32]. Absolute gene expression was deﬁned
determining RPKM as previously described [33]. FastQ raw
data and processed ﬁles are available in the public deposi-
tory NCBI GEO under accession numbers GSE130099 and
GSE130100. Gene set enrichment analysis (GSEA) of a
preranked list log2FC ×−log10(p-value) with average raw
counts ≥20 from three biological replicates from at least one
sample set was performed according to the Hallmark gene
set from the molecular signatures database MSigDBv6.1
(Broad Institute). Heatmaps were generated using Mor-
pheus (Broad Institute).
Cytokine array
For antibody arrays, 5 × 105 were cultured in six-well plates
for 72 h prior to replacing deﬁned medium with 0.5 mL of
serum-free DMEM for 24 h. Conditioned medium was col-
lected and clariﬁed by centrifugation at 2000 g for 10 min.
The supernatant was diluted and applied to the Proteome
Proﬁler™ Human Cytokine Array Kit (R&D Systems®
ARY005B). Spot intensity was quantiﬁed with the Protein
Array Analyzer ImageJ Plugin (http://image.bio.methods.
free.fr/ImageJ/?Protein-Array-Analyzer-for-ImageJ.html)
and normalized to cell number as previously described [14].
Clonogenic assays
Clonogenesis was assessed as previously described [34]. Cells
were ﬁxed in 100% methanol and stained with 0.1% crystal
violet. Representative images were acquired using a Bio-Rad
Chemidoc™ Touch Imaging platform. Colonies were counted
manually and determined as positive if they contained at least
50 cells [35]. Percent area and stain intensity were determined
using the ImageJ plugin ColonyArea [35]. Colony area is a
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measure of well coverage and intensity provides an indication
of the number of cells per colony.
Anchorage-independent growth
The soft agar assay for anchorage-independent growth was
performed as in [36] with modiﬁcations. A base layer of 1.5
mL of 0.6% Difco™ noble agar (BD Biosciences #214230)
in deﬁned growth medium was applied to six-well plates
and allowed to set at room temperature. Cells were then
suspended in 1.5 mL of 0.4% agar and seeded in triplicate
for each independent experiment. Colonies were fed 100 μL
media twice weekly for 28 days. A total of 20 random ﬁelds
were visualized using an EVOS™ FL Cell Imaging System
(Thermo Scientiﬁc™) and colonies (>50 μm in diameter)
were manually counted.
Three-dimensional (3D) spheroid culture
A base layer of 100 µL 1.5% Difco™ noble agar solution in
PBS was applied to a ﬂat-bottomed 96-well plate and
allowed to solidify at room temperature. FT282 cells were
resuspended at 104 cells/mL, 100 µL cell suspension was
seeded each well in FT282 media, and spheroids were
allowed to develop for 4 days. Spheroids were then
embedded in a 20 µL droplet of Matrigel® Growth Factor
Reduced Basement Membrane Matrix (Corning® #356231)
in a 48-well ﬂat-bottom polystyrene tissue culture plate
(Corning® #3548). The spheroids in Matrigel® were overlaid
with 250 µL FT282 media without or with 1 µg/mL dox-
ycycline for 3 days and replenished with fresh media for
additional 2 days, followed by incubation with 10 µM EdU
for 24 h. Matrigel® was depolymerized with Cell Recovery
Solution (Corning® #354253) for 30 min at 4 °C. Spheroids
were washed twice with PBS and ﬁxed in 2% paraf-
ormaldehyde+ 0.2% glutaraldehyde for 10 min for immu-
nohistochemistry analysis. Fixed spheroids were embedded
in Richard-Allan Scientiﬁc™ HistoGel™ Specimen Proces-
sing Gel (Thermo Scientiﬁc™ #HG-4000-012), parafﬁnized,
and 4-µm sections were mounted onto glass slides. Sections
were dewaxed, permeabilized with 0.5% TritonX-100 in
PBS for 5 min, and stained using the Click-iT™ EdU Alexa
Fluor™ 647 Imaging Kit (Invitrogen™ C10340) as per the
manufacturer’s instructions. DAPI staining was used to
label cell nuclei. Slides were imaged with an Olympus
BX61 using a 20× or 40× objective. The number of cells per
spheroid and EdU-positive cells were manually counted.
Clonality/subclonality ratio analysis of TRACERx
nonsmall lung cancer data
The raw data from the TRAcking Cancer Evolution through
therapy (Rx) (TRACERx) study are available at the
European Genome-phenome Archive under accession
number (EGAS00001002247). There was a total of 99 lung
nonsmall cell samples used by the repeated evolution in
cancer (REVOLVER) R Package [37] to determine whether
mutations were clonal or subclonal. The bioinformatics
analyses to obtain somatic alterations and cancer cell frac-
tions (CCFs) were performed by TRACERx. Raw paired
end reads (100 bp) were aligned to the hg19 genomic
assembly using bwa mem (bwa-0.7.7). Picard tools v1.107
was used to clean, sort, and merge ﬁles from the same
patient region and to remove duplicate reads (http://broa
dinstitute.github.io/picard). VarScan2 somatic (v2.3.6) and
MuTect (1.1.4) were used to identify variants. SNV with a
variant allele frequency (VAF) > 2% and called by both
VarScan2 and MuTect, or a VAF > 5% if only called by
VarScan2 were used for downstream analysis. CCFs, which
is the proportion of cancer cells in a sample with a particular
alteration, were determined using PyClone. REVOLVER
uses the CCFs as input. In REVOLVER, an alteration could
be of any type, including single-nucleotide variants, copy-
number alterations, or epigenomics events. The analysis
software for REVOLVER, as well as the data of patients, of
CCFs and whether a variant was clonal or subclonal is
available at https://github.com/caravagn/revolver. The
clonality/subclonality ratios were derived from the infor-
mation provided by the REVOLVER package of whether
mutations were clonal or subclonal. We obtained the clon-
ality of mutations of lung (TRACERx) cohorts, where
patient-level trees capturing the evolution of the cancer
were derived based on multiregion sequencing using
machine learning based on a transfer learning method
[37, 38]. We only considered the 36 AIS escape screen
genes with mutations in ≥3 patients and were clonal or
subclonal in ≥1 patient. When multiple mutations occurred
in the same gene in the same patient, we considered these a
single event. We calculated a clonality/subclonality ratio for
each gene G as follows:
Clonality=subclonality ratioG
¼ Number of patients with a clonal mutation inG
Number of patients with a subclonal mutation inG
Single-sample gene set enrichment analysis
(ssGSEA) of The Cancer Genome Atlas (TCGA) data
We examined the TCGA dataset using cBioportal [39, 40]
and selected patients only with RNASeq (v2) gene
expression, mutation, and copy number data, resulting in an
initial pool of 5,331 samples belonging to 14 cancer types
(bladder urothelial carcinoma; breast adenocarcinoma; cer-
vical and endocervical cancers; glioblastoma multiforme;
head and neck squamous cell carcinoma; lung
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adenocarcinoma; lung squamous cell carcinoma, LUSC;
ovarian serous cystadenocarcinoma; prostate adenocarci-
noma; sarcoma; stomach adenocarcinoma; thyroid carci-
noma; uterine corpus endometrial carcinoma; uterine
carcinosarcoma). Of these samples, 19 patients had cell
cycle and apoptosis regulator 1 (CCAR1) mutations, 5 had
Fas-associated protein with death domain (FADD) muta-
tions, and 21 had NF1 mutations. Two LUSC patients had
CCAR1 mutations and three had NF1 mutations. We
derived an AIS escape signature using the 98 genes iden-
tiﬁed from the AIS escape screen. In the LUSC with
CCAR1 or NF1 mutations, we calculated the level of
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expression of the AIS escape signature in individual patients
using ssGSEA [41] from the GSVA R package [42] on the
RNA-seq data. For the reference group, we only considered
patients with mutation, copy-number aberration, and gene
expression data to ensure the group excluded patients with
alterations in CCAR1, FADD, or NF1. One-sided Wilcoxon
rank sum tests were used to test for statistical signiﬁcance.
Code availability
R code repository for this manuscript is available at https://
github.com/keefe-chan/AKT-induced-senescence-functiona
l-genetic-screen.
Statistical analyses
Pooled data are presented as mean ± SEM values for tri-
plicate biological replicates as indicated in the ﬁgure
legends. Data were presented using GraphPad Prism (8.1)
and P-values < 0.05 were considered signiﬁcant. Statistical
analyses were not used to determine sample size.
Results
Transcriptomic and metabolic proﬁling identify key
AIS signatures
We previously showed normal human cells with chronic
PI3K/AKT/mTORC1 or RAS/ERK activation display
numerous senescence markers [20]. We conﬁrmed con-
stitutively activating either pathway increased SA-ßGal-
positive, decreased EdU-positive cells (Fig. 1a–c), and
decreased levels of the cell cycle regulators phosphorylated
and total Retinoblastoma protein (Rb) and cyclin A
(Fig. 1d). Numerous prosenescence stimuli induce micro-
RNA (miR)-146a expression [26]. To test if this occurs
during AIS, we used an miR-146a promoter-GFP fusion
construct coupled to a constitutive Cherry reporter
(Fig. S1a). FACS analysis at 14 days post transduction (dpt)
showed increased miR-146a expression during AIS
(Fig. S1b, c), indicating miR-146a upregulation is also
common to AIS and OIS.
Previously, we showed p53 mediates proliferative arrest
during AIS, while p16 prevails during OIS, suggesting a
different set of mediators governs each phenotype [20].
Although several OIS mediators are known, those for AIS
are not. To understand and identify whether these
mechanisms are distinct from OIS, we transcriptionally
proﬁled proliferating TERT-immortalized human ﬁbroblasts
(BJ-TERT) and those expressing myrAKT1, a PI3K/AKT/
mTORC1 pathway hyperactivation surrogate, using RNA-
seq (Table S1). At 6 dpt [20], 1003 genes were upregulated
(fold change (FC) ≥ 1.5, FDR < 0.01) and 1350 genes were
downregulated (FC ≤−1.5, FDR ≤ 0.01) compared to con-
trol, highlighting signiﬁcant transcriptional rewiring during
AIS (Fig. 1e). CDKN1A, encoding the cyclin-dependent
kinase inhibitor p21, increased >3-fold, consistent with p53
engagement [20]. LMNB1, encoding lamin B1 was also
downregulated (Fig. 1d), agreeing with impaired nuclear
integrity during senescence contributing to chromatin
reorganization and gene expression changes [43]. We also
observed robust SASP-related gene expression (Fig. S1d)
[14], and qRT-PCR at 14 dpt conﬁrmed CXCL1, IL1A, and
IL1B induction (Fig. S1e–g).
To further distinguish AIS from OIS, we performed
RNA-seq of BJ-TERT ﬁbroblasts expressing constitutively
active HRASV12 at 14 dpt (Table S2), when both had a
similar percentage of senescent cells (Fig. 1a–c). Contrast-
ing AIS, OIS did not show increased CDKN1A expression,
but showed a >2-fold increase over control in CDKN2A,
encoding for p16. We also observed downregulated LMNB1
mRNA (Table S2) and lamin B1 protein (Fig. 1d), and
increased SASP-related gene expression (Fig. S1d). How-
ever, SASP gene expression between OIS and AIS did not
overlap completely, as IGFBP3, IGFBP5, IGBFP7, and
FN1 expression decreased and CXCL3 markedly increased
during OIS compared to AIS.
RNA-seq analysis also revealed RAS/ERK pathway
inhibitor upregulation during AIS: the Sprouty-related
genes SPRED1, SPRED2, and SPRED3; Sproutys SPRY1,
SPRY2, SPRY3, and SPRY4; and the ERK-inactivating dual
speciﬁcity phosphatases DUSP4 and DUSP6 (Fig. 1f). This
concurs with negative feedback signaling during OIS [44]
and indicates transcriptional induction of negative reg-
ulators of RAS/ERK signaling is common to AIS and OIS.
However, AIS distinctly shows diminished RAS/ERK
Fig. 1 Transcriptomic and metabolic proﬁling identify signatures of
AIS. a–d BJ-TERT cells were transduced with pBabe empty vector
control, myrAKT1, or HRASV12 and analyzed at 14 dpt. a Cells were
stained for SA-ßGal activity or EdU. DAPI staining was used to
visualize nuclei. Scale bars= 50 μm. b, c Quantiﬁcation of percentage
of cells with positive staining for b SA-ßGal activity or c EdU. d
Western blots showing senescence markers as well as phosphorylated
and total ERK. GAPDH was probed as a loading control. e Differ-
entially expressed genes (FC ≤−1.5 or FC ≥ 1.5, FDR ≤ 0.01) between
cells undergoing AIS versus proliferating cells, which are down-
regulated (blue), upregulated (red), or not signiﬁcant (black). The top
20 signiﬁcantly upregulated and downregulated genes are indicated. f
Heatmap from RNA-seq data of AIS versus proliferating cells showing
upregulation and FC of inhibitors of RAS/ERK signaling. n= 3 bio-
logical replicates. g Gene set enrichment analysis showing normalized
enrichment score (NES) for signiﬁcantly upregulated and down-
regulated gene sets during AIS or OIS compared to proliferating cells.
h Hierarchical clustering of the top 50 signiﬁcant metabolites in pro-
liferating cells or those undergoing AIS or OIS. Note: The sample
AIS-1 was excluded due to a technical issue in sample processing
independent of sample quality
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signaling at the protein level, while it is robustly increased
during OIS (Fig. 1c).
To further dissect the critical pathways regulating AIS or
OIS, we performed GSEA [45], demonstrating common and
distinct AIS and OIS hallmarks. Both displayed upregulated
oxidative phosphorylation, glycolysis, unfolded protein
response, mTORC1 signaling, and TNFα signaling via NF-
κB (Fig. 1g; Table S3); and downregulated estrogen
response, mitotic spindle, apical junction, UV response, and
cholesterol homeostasis (Fig. 1g; Table S4).
In contrast, interferon response and epithelial mesench-
ymal transition gene sets were enriched during AIS and
downregulated during OIS. Diminished interferon response
during OIS agrees with antagonism by p38 pathway
activation [46]. Also, E2F targets and G2M checkpoint gene
sets were downregulated during AIS and upregulated during
OIS, reﬂecting the distinct mechanisms for engaging p53
and p16 [20]. Collectively, these data demonstrate con-
stitutive PI3K/AKT/mTORC1 or RAS/ERK pathway acti-
vation in nontransformed cells evokes overt cell cycle arrest
and inﬂammatory phenotypes, however important subtleties
underlie how each drives its overarching senescence
phenotype.
Another critical OIS feature is markedly altered meta-
bolic activity, featuring decreased glycolysis, increased
lipid content, impaired mitochondrial function, and
increased oxidant formation compared to proliferating cells
[47]. To understand whether similar metabolic changes
Fig. 2 A genome-wide RNAi screen reveals critical regulators of AIS
maintenance. a Schematic representation of screen design. BJ-TERT
ﬁbroblasts were retrovirally transduced with constitutively active
myristoylated AKT1. At 3 dpt, senescent cells were enriched by
puromycin selection for 3 days. At 6 dpt, senescent cells were reverse
transfected in arrayed format with SMARTpool siRNAs in 384-well
plates. At 12 dpt (6 days post transfection), cells were ﬁxed and stained
for SA-ßGal activity and EdU for proliferation. DAPI staining was
used to label cell nuclei for quantiﬁcation of cell number. b Summary
of screen results. Hits were determined based on statistical robust Z-
score cutoffs for cell number, average EdU ﬂuorescence intensity, and
nuclear area normalized to nontargeting siRNA (siOTP-NT). RNA-seq
of BJ-TERT cells (Supplementary Table S1) was used to exclude 3828
genes not expressed to minimize false positives. c Plot of siRNA target
versus robust Z-score for cell number normalized to nonsilencing
control in the primary screen as indicated in b. d First-order network
generated from secondary deconvolution screen hits as indicated in b.
e Regulators of AIS maintenance are enriched during the clonal evo-
lution of human lung cancer. Plot of clonality/subclonality ratios from
the screen dataset (red) versus 100 out of 100,000 random gene set
distributions (black)
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occurred during AIS, we proﬁled proliferating cells and
those undergoing AIS or OIS using GC-MS (Table S5).
Principal component (Fig. S2a) and hierarchical clustering
(Fig. 1h) analyses showed clear separation between the
metabolites generated by proliferating cells versus those
undergoing AIS or OIS. Of the signiﬁcant metabolites (BH
adjusted <0.05), 27 were common to AIS or OIS (Fig. S2b).
Six metabolites (glutamate, cysteine, glutamine, glyceric
acid, ribitol, and proline.trans.4.hydroxyl.L) were speciﬁ-
cally upregulated during AIS. Metabolic pathway enrich-
ment analysis also demonstrated AIS and OIS had enriched
urea cycle, Warburg effect, glycine and serine metabolism,
malate-aspartate shuttle, and phenylalanine and tyrosine
metabolism pathways compared to proliferating cells
(Fig. S2c, d and Table S6). These pathways were more
signiﬁcantly enriched during OIS, possibly reﬂecting how
the DDR reinforces senescence-associated metabolic
rewiring [47]. Together with our previous ﬁndings, these
transcriptomics and metabolomics data demonstrate AIS
and OIS have common and distinct molecular
underpinnings.
A genome-wide RNAi screen identiﬁes novel AIS
mediators
Multiple OIS mediators have been uncovered [48–50]. To
determine the essential AIS regulators and identify
mechanisms overcoming AIS, we assayed AIS escape using
high-throughput microscopy [28] in a genome-wide RNAi
screen of BJ-TERT cells retrovirally transduced with myr-
AKT1 (Fig. 2a, b; Table S6). Tumor protein p53 (TP53)
siRNA was used as an AIS escape positive control. At 12
dpt (6 days post transfection), we quantiﬁed cell number,
EdU incorporation, and nuclear area (Table S7). Senescent
cells were fewer in number and had larger nuclei due to
altered nuclear integrity and chromatin reorganization [43].
Positive hits restoring cell proliferation in the primary
screen were siRNAs with a robust Z-score scoring ≥2 stan-
dard deviations above the plate mean (≥10% increased cell
number) (Fig. 2b, c). Gene ontology analysis of the primary
screen data revealed functional processes including
responses to compounds and lipids, regulation of cell
communication, and positive regulation of NF-κB signaling
(Table S8).
We triaged the 838 hits based on two parameters: aver-
age EdU ﬂuorescence intensity (robust Z-score ≥ 1.5, ≥17%
increase) and nuclear area (robust Z-score ≤−2, ≥12%
decrease), as proliferating cells would show restoration of
these markers. The top 378 hits were assessed in secondary
screening, where SMARTpools were deconvoluted into the
four individual siRNA duplexes. Genes with ≥2 siRNAs
recapitulating the SMARTpool phenotype were considered
hits (Table S9). Gene network analysis of the 98 hits
identiﬁed TP53 (the top hit), and v-rel avian reticu-
loendotheliosis viral oncogene homolog A (RELA) as nodes
displaying the highest degree and betweenness (Fig. 2d and
Table S10), indicating they integrate most signaling inputs
within the AIS network. Also, 10% of the hits were asso-
ciated with cellular metabolism (SLC15A2, SLC25A13,
SLC7A6, SLC20A1, SLC7A2, GGH, SLC22A11, NOX5,
NOXO1, CBS, and CTNS), suggesting extensive metabolic
reprogramming during AIS, consistent with our metabo-
lomics analysis. Inositol 5-phosphatase INPP5J, a screen hit
and AKT negative regulator, was a recently identiﬁed breast
cancer suppressor [51], supporting our screen’s robustness.
Given the screen hits maintain AIS, their loss or inacti-
vation may occur during PI3K/AKT/mTORC1-driven
tumorigenesis. To test this concept, we interrogated the
TRACERx study, which utilizes multiregion exome
sequencing to determine clonal evolutionary processes
during tumor development in human nonsmall cell lung
cancer of which 50–70% display aberrant PI3K/AKT/
mTORC1 activation [37, 38]. Mutations were classiﬁed as
clonal (present in all cells), occurring early during tumor
evolution, or subclonal (present in a subset), occurring later.
To calculate whether the AIS escape screen genes had
higher clonality/subclonality ratios than those not in the
screen, we subsampled 100,000× gene sets containing 36
random genes (Fig. 2e). While the actual distribution’s
average clonality/subclonality ratio was 3.06, the random
distributions’ was 2.52. Comparing the skewness of the
screen and random distributions, we empirically derived a
permutation P-value= 0.03, suggesting mutations in the
AIS escape screen genes tend to be clonal than other genes.
The genes with signiﬁcant clonality/subclonality ratios were
TP53, PTPRZ1, DENND5, KLHL17, MOCOS, and TGM2,
highlighting the potential contribution of these AIS med-
iators to the early development of lung cancer.
RELA regulates AIS in BJ-TERT cells
During OIS the NF-κB pathway drives inﬂammatory sig-
naling [52, 53]. Although TP53 and RELA, encoding the
p65 subunit of the canonical NF-κB signaling complex, are
the AIS network’s central nodes, NF-κB activation during
AIS has not been evaluated. To test this, we generated BJ-
TERT cell lines expressing inducible shRNAs (Fig. S3a)
against RELA and TP53 as a positive control, enabling
longer-term functional studies. After transducing BJ-TERT
cells with myrAKT1 or HRASV12 promoting AIS or OIS,
we induced control or RELA knockdown with doxycycline
(Fig. S3b) and conﬁrmed p65 knockdown (Fig. S3c). To
test AIS stability and whether RELA depletion could over-
come AIS, we stained for SA-ßGal activity and EdU at 19
dpt (Fig. S3d). While cells during AIS or OIS were EdU-
negative and SA-ßGal positive, RELA knockdown
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decreased SA-ßGal-positive and increased EdU-positive
cells, indicating cell cycle re-entry (Fig. S3e, f). To further
validate the AIS-escaping cells’ proliferative potential upon
RELA depletion, we performed clonogenic assays, demon-
strating enhanced colony formation (Fig. S3g–i).
To test RELA knockdown’s impact on the SASP, we
examined conditioned medium on cytokine membrane
arrays (Fig. S3j). CXCL1, G-CSF, IL-6, and IL-8 were
upregulated during AIS and OIS (as a positive control)
compared to proliferating cells. RELA knockdown in
myrAKT1-expressing cells decreased G-CSF and IL-6 but
not CXCL1 or IL-8, indicating p65 regulates a subset of
SASP cytokine production during AIS in BJ-TERT cells
(Fig. S3j, k).
CCAR1, FADD, and NF1 are novel AIS mediators
We next investigated AIS escape screen mediators involved
in tumor suppression but not yet implicated in regulating
senescence. CCAR1 expression is reduced in poorly
Fig. 3 Functional validation of AIS mediators. a–c BJ-TERT cells
expressing inducible shRNA were transduced with myrAKT1, treated
with doxycycline and assessed for AIS escape by quantiﬁcation of
percentage of cells with positive staining for a SA-ßGal activity or b
EdU, or c western blotting for senescence markers after 19 days. d, e
BJ-TERT cells expressing inducible myrAKT1 or HRASV12 and
inducible shRNA were treated with doxycycline and assessed for AIS
bypass in d colony formation assays after 19 days. e Quantiﬁcation of
colony number in d. Data are expressed as mean ± SEM. n= 3
experiments. *P < 0.05; **P < 0.01; ****P < 0.0001 by one-way
ANOVA as compared with shREN for each oncogene. ###P < 0.01;
####P < 0.0001 by two-way ANOVA as compared with myrAKT1 and
corresponding shRNA
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differentiated breast cancers and FADD expression is
downregulated during thyroid adenocarcinoma progression,
with both cancers showing aberrant PI3K/AKT/mTORC1
pathway activation [54, 55]. The tumor suppressor NF1, the
second-ranked hit behind p53 (Table S9), is implicated in
melanoma though its role in AIS is unknown [18, 44, 56].
To functionally validate these mediators, we generated
BJ-TERT cell lines expressing doxycycline-inducible
shRNAs. At 6 dpt with myrAKT1, we induced shRNA
knockdown and assessed SA-ßGal and EdU staining at 19
dpt (Fig. 3a, b). Depleting TP53, CCAR1, FADD, and NF1
showed decreased SA-ßGal-positive and increased EdU-
positive cells compared to control, indicating signiﬁcant
AIS disengagement.
To determine mediator speciﬁcity, we compared senes-
cence signaling in these cell lines during AIS and OIS.
CCAR1, FADD, and NF1 knockdown levels were equiva-
lent between AIS and OIS (Fig. 3c). Control cells under-
going AIS or OIS had low levels of phosphorylated Rb,
lamin B1, cyclin A, and p21. TP53 knockdown increased
phosphorylation of Rb, lamin B1, and cyclin A, and
decreased p21 during AIS, indicating cell cycle re-entry/
senescence escape. HRASV12-expressing cells with TP53
knockdown also showed increased phosphorylated Rb and
cyclin A, and decreased p21 but unlike myrAKT1-
expressing cells, did not display increased lamin B1.
CCAR1 depletion increased phosphorylated Rb, lamin B1,
and cyclin A in myrAKT1-expressing cells and markedly in
HRASV12-expressing cells, suggesting it is a common
mediator. FADD knockdown in myrAKT1-expressing cells
increased phosphorylated Rb but not in HRASV12-
expressing cells. Intriguingly, NF1 depletion robustly
Fig. 4 NF1-mediated suppression of RAS/ERK signaling is required
for AIS. a–c BJ-TERT cells were transduced with pBabe, myrAKT1,
or HRASV12 and analyzed after 14 days. a qRT-PCR showing rela-
tive NF1 mRNA expression normalized to GAPDH and pBabe control.
Data are expressed as mean ± SEM. n= 3 experiments. b Western
blotting of NF1, PI3K/AKT/mTORC1, or RAS/ERK pathway acti-
vation and senescence signaling. Actin was probed as a loading con-
trol. c Quantiﬁcation by densitometry of relative NF1 protein
expression normalized to actin loading control. Data are expressed as
mean ± SEM. n= 3 experiments. *P < 0.05 by one-way ANOVA as
compared with pBabe control. d BJ-TERT cells expressing inducible
NF1-GRD were treated without or with doxycycline for 3 days and
analyzed for active RAS by western blotting. e–i BJ-TERT cells
expressing inducible NF1 shRNA #2 and ER-FLAG-NF1-GRD were
transduced with myrAKT1 and left untreated or treated with dox-
ycycline at 6 dpt in the absence or presence of 40 nM 4-OHT for
13 days. e Experimental design. f Western blots showing phos-
phorylated and total ERK expression upon NF1 depletion and ER-
FLAG-NF1-GRD expression. g Cells were stained for SA-ßGal
activity and EdU. Scale bars= 50 μm. h, i Quantiﬁcation of percentage
of cells with positive staining for h SA-ßGal activity or i EdU. Data are
expressed as mean ± SEM. n= 3 experiments. **P < 0.01; ****P <
0.0001 by one-way ANOVA as compared with untreated control
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increased phosphorylation of Rb, lamin B1, and cyclin A
only in myrAKT1-expressing cells, indicating speciﬁcity
for NF1 during AIS. Furthermore, p21 expression was
unchanged with all knockdowns except for TP53 during
AIS, supporting p53-independent senescence escape
mechanisms.
We further interrogated these mediators in OIS and AIS
bypass using BJ-TERT cell lines coexpressing doxycycline-
inducible shRNAs and inducible myrAKT1 or HRASV12.
Clonogenic assays demonstrated enhanced colony forma-
tion upon knockdown of the mediators compared to control,
indicating AIS bypass (Fig. 3d, e). Colony formation was
increased with knockdown of these genes upon constitutive
RAS/ERK activation, albeit less robust than observed for
AIS, even for TP53, indicating the mediators tested play a
more signiﬁcant role in regulating AIS than OIS.
We also tested the senescence mediators in primary
human diploid IMR-90 lung ﬁbroblasts (Fig. S4a). IMR-90
cells undergoing AIS following myrAKT1 transduction
stained strongly with SA-ßGal and were EdU-negative.
Depleting TP53, CCAR1, FADD, or NF1 in myrAKT1-
expressing cells showed reduced SA-ßGal-positive and
increased EdU-positive cells. In contrast, their knockdown
in proliferating cells did not affect EdU or SA-ßGal staining
(Fig. S4b–d). Intriguingly, unlike in BJ-TERT cells, RELA
depletion could not cause AIS escape in IMR-90 cells,
Fig. 5 Overexpression of an NF1-GRD fragment promotes an AIS-like
phenotype in p53-mutant fallopian tube epithelial cells. a Western
blots showing NF1 and phosphorylated and total ERK expression in
FT282 cells expressing MSCV empty vector control or myrAKT1 and
control (REN) or NF1 shRNA #2. Actin was probed as loading con-
trol. b Quantiﬁcation of soft agar colony number from anchorage-
independent growth assays after 28 days for FT282 cells expressing
MSCV empty vector control or myrAKT1 and control (REN) or
NF1 shRNA #2. Data are expressed as mean ± SEM. n= 3 experi-
ments. ****P < 0.0001 by one-way ANOVA as compared with shREN.
c–h FT282 cells depleted of NF1 (shNF1 #2) expressing inducible
NF1-GRD and MSCV empty vector control or myrAKT1 were treated
without or with doxycycline. c Western blotting for markers of pro-
liferative arrest after 3 days. GAPDH was probed as a loading control.
d Quantiﬁcation of relative cyclin A expression normalized to GAPDH
in c. e Cells were stained for SA-ßGal activity or EdU after 6 days.
DAPI staining was used to visualize nuclei. Scale bars= 50 μm. f, g
Quantiﬁcation of percentage of cells with positive staining for f SA-
ßGal activity or g EdU. h Quantiﬁcation of soft agar colony number
from anchorage-independent growth assays after 28 days. Data are
expressed as mean ± SEM. n= 3 experiments. ***P < 0.001; ****P <
0.0001 by one-way ANOVA as compared with empty vector control—
Dox
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consistent with RELA regulation of senescence being cell
type speciﬁc [57].
To further ascertain clinical relevance, we selected
TCGA patients with mutations/copy number alterations in
NF1, FADD, and/or CCAR1 using cBioportal [39, 40]. We
derived an AIS escape signature comprising the 98 screen
hits and determined its expression in individual LUSC
patients across the TCGA cohort using ssGSEA on the
RNA-seq data. While no patients had FADD alterations in
LUSC, when we compared patients with mutations in NF1
(n= 3) or CCAR1 (n= 2) versus those without, the AIS
escape signature was enriched (P= 0.03) of (Fig. S5).
These data demonstrate some patients with mutations in
AIS mediators also have gene expression changes asso-
ciated with AIS escape mechanisms.
NF1-mediated suppression of RAS/ERK signaling
maintains AIS
Our RNA-seq and protein expression analyses revealed
suppression of RAS/ERK signaling is a key AIS hallmark
(Fig. 1d, f). We also demonstrated NF1 loss results in AIS
escape and bypass (Fig. 3a–e). Given NF1 is a RAS
GTPase-activating protein [56], we hypothesized NF1-
mediated suppression of RAS/ERK signaling maintains
AIS. RNA-seq (Table S1) and qRT-PCR (Fig. 4a) analyses
showed unchanged NF1 mRNA expression upon AIS.
However, NF1 protein expression increased twofold during
AIS but not OIS compared to proliferating cells (Fig. 4b, c),
coinciding with decreased phosphorylated ERK during AIS.
We tested if functional NF1 restoration could prevent
AIS escape. The NF1 GTPase-activating protein-related
domain (GRD) is sufﬁcient to inactivate RAS [58] (Fig. 4d).
We thus generated a 4-hydroxytamoxifen (4-OHT)-induci-
ble estrogen receptor (ER) FLAG-tagged NF1-GRD fusion,
and used a 4-OHT dose resulting in a phosphorylated ERK
level comparable to that during AIS (Fig. 4e, f). BJ-TERT
cells coexpressing doxycycline-inducible NF1 shRNA and
4-OHT-inducible NF1-GRD were made senescent upon
myrAKT1 transduction, and were treated without or with
doxycycline to induce NF1 knockdown and AIS escape.
Doxycycline-treated cells were also treated without or with
4-OHT. While NF1 depletion caused AIS escape, cells with
NF1 knockdown and simultaneous NF1-GRD induction
remained senescent (Fig. 4g–i), indicating on-target shRNA
speciﬁcity and AIS maintenance by restoring NF1-mediated
suppression of RAS/ERK signaling.
Overexpressing an NF1-GRD fragment blocks p53-
mutant fallopian tube epithelial cell transformation
Given 50% of cancers harbor p53-inactivating alterations
we investigated whether we could exploit the screen
candidates to reinstate AIS in cells with hyperactive AKT
and p53 deﬁciency. The fallopian tube secretory epithelial
cell line FT282 [25] models the premalignant precursor to
high-grade serous ovarian cancers (HGSOC), of which 96%
harbor TP53 mutations and >35% display constitutive
PI3K/AKT/mTORC1 pathway activation [59]. Further-
more, 20% harbor NF1-inactivating mutations and/or gene
breakage [60, 61], supporting a cooperative role for NF1
loss in HGSOC.
We generated isogenic control or myrAKT1-expressing
FT282 cells and conﬁrmed functional expression (Fig. 5a).
Anchorage-independent growth assays demonstrated myr-
AKT1 could transform the FT282 cells (Fig. 5b), while NF1
knockdown alone was insufﬁcient. However, NF1 loss
increased soft agar colony formation in FT282 myrAKT1-
expressing cells, indicating cooperation with PI3K/AKT/
mTORC1 activation and mutant p53 to drive transformation
(Fig. 5b).
NF1-deﬁcient FT282 cells showed increased phos-
phorylated ERK, which was reduced upon myrAKT1
expression (Fig. 5c), supporting our observation in BJ-
TERT cells that hyperactive AKT induces feedback sup-
pression of RAS/ERK signaling, which NF1 loss overcame
(Figs. 1f and 4b). NF1-GRD overexpression further
decreased phosphorylated ERK and diminished Rb and
cyclin A (Fig. 5c, d), indicating the NF1-GRD induces cell
cycle arrest markers in p53-mutant AIS-bypassing cells.
NF1-GRD overexpression increased SA-ßGal-positive and
reduced EdU-positive cells (Fig. 5e–g). We also cultured
3D spheroids of FT282 cells coexpressing activated AKT
and inducible NF1-GRD (Fig. S6a). Upon NF1-GRD
induction, we observed fewer cells per spheroid and EdU-
positive cells (Fig. S6b, c). Furthermore, NF1-GRD over-
expression ablated anchorage-independent growth of the
transformed p53-mutant FT282 myrAKT1-expressing cells
(Fig. 5h). Collectively, these data highlight engagement of
an intact NF1-dependent, p53-independent pathway rein-
stating AKT-driven senescence.
Discussion
We surmised understanding AIS would uncover insights
into potential tumor-suppressive and resistance mechanisms
and provide new avenues for future therapeutic exploitation
targeting PI3K/AKT/mTORC1-driven cancers.
RNA-seq and metabolomic analyses of cells undergoing
AIS conﬁrmed many hallmarks of prototypical OIS
including cell cycle gene downregulation, SASP gene
upregulation, lamin B1 downregulation, altered metabo-
lism, and miR-146a upregulation upstream of NF-κB sig-
naling [26]. However, our studies also identify speciﬁc
mechanisms of AIS, consistent with our previous study
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showing AIS is p53-dependent and DNA damage inde-
pendent [20]. We demonstrate AIS suppresses RAS/ERK
signaling by upregulating inhibitors of RAS/ERK and NF1,
distinct from the ﬁnding that constitutive BRAF signaling
suppressed the PI3K/AKT/mTORC1 pathway to induce
senescence [44]. Our ﬁnding that depleting NF1 caused AIS
escape reinforces mutually exclusive senescence induction
mechanisms. Restoring NF1’s ability to inhibit RAS/ERK
signaling in NF1-depleted cells rescued AIS (Fig. 4e–i).
Intriguingly, NF1 was posttranscriptionally upregulated
during AIS but not OIS (Fig. 4a–c), which we hypothesize
is due to enhanced synthesis or stabilization, as we showed
for p53 [20].
Our ﬁndings also support the hypothesis that NF1-
mediated suppression of RAS/ERK signaling is a key AIS
tumor-suppressive mechanism. NF1 loss enhances trans-
formation of p53-mutant fallopian tube epithelial cells
expressing activated AKT (Fig. 5b). Conversely, over-
expressing an NF1-GRD fragment reinstated senescence
and blocked transformation (Fig. 5c–g). Consistent with
this, a forward genetic screen in malignant peripheral nerve
sheath tumors (MPNSTs) identiﬁed cooperation between
Pten and Nf1 loss, and reduced PTEN and NF1 is associated
with progression to high-grade MPNSTs [62].
As NF1 deﬁciency mediated escape from BRAF-driven
OIS and BRAF inhibitor resistance in melanoma, which
could be combatted with MEK inhibitors [18, 19], we
hypothesize NF1 loss may be a key targetable mechanism
of resistance to PI3K/AKT/mTORC1 inhibitors. While our
ﬁndings and preclinical studies have demonstrated suc-
cessful targeting of NF1 loss, clinical translation has proved
challenging. However, the MEK inhibitor selumetinib has
shown promise in clinical trials treating NF1-mutant neu-
roﬁbromatosis and plexiform neuroﬁbroma patients [63].
Inhibiting MEK could reinstate AIS in cancers with
deregulated PI3K/AKT/mTORC1 signaling and NF1 loss.
Our ﬁndings provide additional rationale for employing
combination therapies targeting both the RAS/ERK and
PI3K/AKT/mTORC1 pathways [64–66]. Indeed, a phase 2
clinical trial is planned combining selumetinib and the
mTORC1 inhibitor sirolimus for MPNST patients [67].
We also functionally validated CCAR1 and FADD as
novel AIS regulators. Potential therapeutic opportunities
targeting them to reinstate AIS include a CCAR1 functional
mimetic CFM-4 having in vivo efﬁcacy in human nonsmall
cell lung cancer treatment [68], and a dual-speciﬁc antibody
against death receptors 4 and 5 upstream of FADD showing
proapoptotic activity in human breast, ovarian, and colon
cancer xenografts [69].
We identiﬁed substantial metabolic rewiring during AIS
similar to that during OIS. Moreover, as 10% of the AIS
escape screen hits are associated with metabolism, these
data suggest metabolically reprogramming cancer cells with
chronic PI3K/AKT/mTORC1 activation can re-engage AIS.
This approach succeeded in a study of melanocytes
expressing BRAFV600E, which undergo OIS and suppress the
mitochondrial gatekeeper enzyme pyruvate dehydrogenase
kinase 1 (PDK1) [70]. Inhibiting PDK1 caused BRAFV600E
inhibitor-resistant melanoma regression. From the TRA-
CERx human lung cancer data analysis (Fig. 2e), we also
found several AIS escape genes that could be involved in
tumor evolution. Understanding how these genes regulate
AIS will provide insight into the evolution of PI3K/AKT/
mTORC1-driven cancers [2, 4, 7, 71].
A previous study demonstrated that while IR-induced
senescent IMR-90 cells upregulated proapoptotic genes,
FOXO4-dependent prosenescence signaling prevented
apoptosis. Strikingly, FOXO4 inhibition promoted apopto-
sis [72]. Similarly, we hypothesize the AIS network harbors
multiple signaling inputs including prosenescence and
proapoptotic signaling (Fig. 6). Disrupting key pathways in
the network can drive AIS escape, providing insight into
tumor development and targeted therapy resistance
mechanisms, which can potentially be harnessed to reinstate
senescence or drive PI3K/AKT/mTORC1-driven cancers
toward death.
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